Compare NNVC & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNVC | MYO |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 44.8M |
| IPO Year | 2008 | 2017 |
| Metric | NNVC | MYO |
|---|---|---|
| Price | $1.75 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 349.7K | ★ 901.7K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $9.10 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.85 | $0.61 |
| 52 Week High | $2.23 | $2.20 |
| Indicator | NNVC | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 61.20 | 37.44 |
| Support Level | $1.18 | $0.75 |
| Resistance Level | $1.90 | $0.99 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 78.18 | 13.23 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.